Ambys Medicines fetches $60 mln Series A

Redwood City, California-based Ambys Medicines, a developer of new medicines patients suffering from chronic liver diseases, has launched with $60 million in Series A financing. The investors were Third Rock Ventures and Takeda.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!